Education
About Us
Working with TipRanks
Follow Us
Biodesix (BDSX)
NASDAQ:BDSX
Earnings Data
Report Date
Mar 17, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.94Last Year’s EPS
-1.2Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Biodesix showed strong revenue growth, improved gross margins, and significant progress in lung diagnostics and development services. However, unresolved issues with Medicare Advantage payments and an existing net loss highlight ongoing challenges. Overall, the achievements and positive trends in growth and operational improvements suggest a positive outlook.Company Guidance
Revenue Growth
Third quarter total revenue was $21.8 million, a 20% increase over the prior year. Lung diagnostic testing revenue for the third quarter of 2025 was $19.8 million, representing 13% growth in test volumes and 16% growth in revenue.
Improved Gross Margins
Gross margin percentage in the third quarter of 2025 was 81%, up 400 basis points from 77% in the third quarter of 2024.
Adjusted EBITDA Improvement
Adjusted EBITDA was a loss of $4.6 million, an improvement of 18% year-over-year and 36% over the second quarter.
Development Services Growth
Development services revenue was $1.9 million in the quarter, representing 97% year-over-year growth.
Expansion of Sales Force
The company increased its sales force to an average of 85 sales reps in the field, with plans for further expansion to 93-97 reps in the fourth quarter.
Progress in Lung Diagnostics
Nodify Lung testing saw increased adoption, with primary care test orders growing 75% over the third quarter of '24. Digital ordering increased by 43% over last year.
Pipeline and Partnerships
Biodesix expanded its product development partnership with Bio-Rad Laboratories and presented multiple studies supporting its product pipeline.
Increased Revenue Guidance
The company increased its full-year 2025 revenue guidance to $84 million to $86 million.
BDSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BDSX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 03, 2025 | $6.34 | $7.60 | +19.87% |
Aug 07, 2025 | $8.94 | $8.01 | -10.40% |
May 13, 2025 | $7.18 | $4.40 | -38.72% |
Mar 03, 2025 | $14.26 | $14.40 | +0.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biodesix (BDSX) report earnings?
Biodesix (BDSX) is schdueled to report earning on Mar 17, 2026, After Close (Confirmed).
What is Biodesix (BDSX) earnings time?
Biodesix (BDSX) earnings time is at Mar 17, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BDSX EPS forecast?
BDSX EPS forecast for the fiscal quarter 2025 (Q4) is -0.94.